Canaccord Genuity Maintains a 'Speculative Buy' on Æterna Zentaris (AEZS); Q4 Results: Delay for Phase III Multiple Myeloma Trial, but CRC Remains on Track
Tweet Send to a Friend
Canaccord Genuity maintains a 'Speculative Buy' on Æterna Zentaris (NASDAQ: AEZS), PT $2.75.
Canaccord analyst says, "The company reported a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "The company reported a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
